OBT

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Oxford, England & Ingelheim, Germany:  The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell…

Read More »